GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Galderma Group AG (OTCPK:GALDY) » Definitions » EPS (Basic)

GALDY (Galderma Group AG) EPS (Basic) : $0.19 (TTM As of Dec. 2024)


View and export this data going back to 2024. Start your Free Trial

What is Galderma Group AG EPS (Basic)?

Galderma Group AG's basic earnings per share (Basic EPS) for the six months ended in Dec. 2024 was $0.15. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Dec. 2024 was $0.19.

Galderma Group AG's EPS (Diluted) for the six months ended in Dec. 2024 was $0.15. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Dec. 2024 was $0.19.

Galderma Group AG's EPS without NRI for the six months ended in Dec. 2024 was $0.17. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Dec. 2024 was 0.21.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

Galderma Group AG EPS (Basic) Historical Data

The historical data trend for Galderma Group AG's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Galderma Group AG EPS (Basic) Chart

Galderma Group AG Annual Data
Trend Dec23 Dec24
EPS (Basic)
-0.05 0.19

Galderma Group AG Semi-Annual Data
Jun23 Dec23 Jun24 Dec24
EPS (Basic) - -0.05 0.04 0.15

Galderma Group AG EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

Galderma Group AG's Basic EPS for the fiscal year that ended in Dec. 2024 is calculated as

Basic EPS (A: Dec. 2024 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(231-0)/1187.577
=0.19

Galderma Group AG's Basic EPS for the quarter that ended in Dec. 2024 is calculated as

Basic EPS (Q: Dec. 2024 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(184-0)/1187.323
=0.15

EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was $0.19

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Galderma Group AG  (OTCPK:GALDY) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Galderma Group AG EPS (Basic) Related Terms

Thank you for viewing the detailed overview of Galderma Group AG's EPS (Basic) provided by GuruFocus.com. Please click on the following links to see related term pages.

Galderma Group AG Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Galderma Group AG (OTCPK:GALDY) » Definitions » EPS (Basic)
Comparable Companies
XSWX:SDZ XSWX:SFZN XSWX:PPGN XSWX:CURN ZTS XTER:MRK NSE:SUNPHARMA TSE:4502 LSE:HLN HKSE:03692 NSE:DIVISLAB XTAE:TEVA ITCI SZSE:000538 UTHR BOM:500087 TSE:4507 SHSE:688506 NSE:TORNTPHARM BOM:543904
Traded in Other Exchanges
GDERF:USA GALDz:UK PY30:Germany GALD:Switzerland
Address
Zahlerweg 10, Zug, CHE, 6300
Website
https://www.galderma.com
Galderma was formed in 1981 as a joint venture between Nestle and L'Oreal. It subsequently became a subsidiary of Nestle, called Nestle Skin Health, before being carved out and launched as a standalone company in 2019, acquired by a consortium led by Sweden-based EQT fund. The company went public in March 2024 and is listed on the SIX Swiss exchange. Galderma's science-based portfolio spans multiple dermatology categories, including injectable aesthetics, dermatological skincare, and therapeutic dermatology. It derives around 45% of net sales from the US and employs around 6,600 people.